StreetAlpha.app
Home › Stocks › PLSE

Pulse Biosciences, Inc. (PLSE)

Healthcare
Members
LATEST PRICE

Pulse Biosciences develops nanosecond pulsed energy devices for tissue ablation, with a focus on treating heart rhythm conditions. PLSE reports earnings on Thu, Nov 5, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print.

Prices, price targets and earnings estimates for PLSE are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is PLSE in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
Strong Buy
Based on 5 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
5firms
5 Buy0 Hold0 Sell
Each firm's latest rating on PLSE in the past 90 days
Average 12-month target
Price targets for PLSEThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
OppenheimerMaintained
Oct 13Buy
Canaccord GenuityTarget raised
Oct 6Buy
BTIGInitiated
Sep 23Buy
Freedom Capital MarketsInitiated
Sep 9Buy
NeedhamInitiated
Aug 17Buy
DateFirmActionRatingPrice target
Oct 13OppenheimerMaintainedBuy
Oct 6Canaccord GenuityTarget raisedBuy
Sep 23BTIGInitiatedBuy
Sep 9Freedom Capital MarketsInitiatedBuy
Aug 17NeedhamInitiatedBuy
Loading…

Whale Options Flow

90D

No whale options trades in PLSE in the last 90 days.

Loading…

Dark Pool

30D
Prints
1
Notional
Members
Largest print
Members
Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PLSE is in one of them and how their past PLSE trades turned out.

See how it works→ View all auto pilots→
PLSE in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered PLSE in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Pulse Biosciences

Pulse Biosciences is a medical device company based in Hayward, California. It develops technology that delivers very short pulses of electrical energy to clear or kill targeted cells without heating the surrounding tissue. Its nPulse System and Vybrance Percutaneous Electrode are designed for surgeons and clinical sites performing soft tissue ablation. The company is also developing cardiac surgical and catheter devices for treating atrial fibrillation, a heart rhythm condition.

Headquarters
Hayward, CA
Summary based on the company’s 2026 annual report (10-K) ↗